干粉吸入器
医学
吸入
重症监护医学
哮喘
2019年冠状病毒病(COVID-19)
全身疗法
临床试验
干咳
囊性纤维化
吸入器
免疫学
疾病
内科学
麻醉
乳腺癌
传染病(医学专业)
癌症
作者
Yuqing Ye,Ying Ma,Jesse Zhu
标识
DOI:10.1016/j.ijpharm.2022.121457
摘要
Dry powder inhalation therapy has been shown to be an effective method for treating respiratory diseases like asthma, Chronic Obstructive Pulmonary Diseases and Cystic Fibrosis. It has also been widely accepted and used in clinical practices. Such success has led to great interest in inhaled therapy on treating systemic diseases in the past two decades. The current coronavirus (COVID-19) pandemic also has increased such interest and is triggering more potential applications of dry powder inhalation therapy in vaccines and antivirus drugs. Would the inhaled dry powder therapy on systemic disorders be as encouraging as expected? This paper reviews the marketed and in-development dry powder inhaler (DPI) products on the treatment of systemic diseases, their status in clinical trials, as well as the potential for COVID-19 treatment. The advancements and unmet problems on DPI systems are also summarized. With countless attempts behind and more challenges ahead, it is believed that the dry powder inhaled therapy for the treatment of systemic disorders still holds great potential and promise.
科研通智能强力驱动
Strongly Powered by AbleSci AI